Product Description: 2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1[1][2][3].
Applications: Neuroscience-Neuromodulation
Formula: C11H14N5Na3O10P2S
References: [1]Zhang FL, et al. P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther. 2002;301(2):705-713./[2]Sak K, et al. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch Biochem Biophys. 2002;397(1):131-136./[3]Macfarlane DE, et al. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest. 1983;71(3):420-428.
CAS Number: 475193-31-8
Molecular Weight: 539.24
Compound Purity: 98.0
Research Area: Neurological Disease
Solubility: 10 mM in DMSO
Target: P2Y Receptor
English
Deutsch
